CTLA4 and non-small cell lung carcinoma: Anti-PD-1 therapies (alone or in combination) outperformed anti-PD-L1 and anti-CTLA-4 therapies in OS.<h4>Conclusions</h4>This meta-analysis highlights how the efficacy of ICIs in advanced NSCLC varies by age and PS.